NAD+ classification
Is NAD+ a peptide?
No. NAD+ is not a peptide, even though one of the 11 seller pages we read on October 11, 2026 advertises it as "the fountain of youth peptide". A peptide is a chain of amino acids. NAD+ (nicotinamide adenine dinucleotide, often written NAD) contains none. The National Library of Medicine defines it as a coenzyme in which a nicotinamide unit and an adenosine unit are joined through phosphate groups. Its molecular weight is 663.4, about a fifth of the peptide sermorelin. The difference matters when you buy, because FDA decisions and study results for peptides do not transfer to NAD+. NAD+ has its own line on FDA's compounding list and its own small set of human studies.
Tests the peptide label against the National Library of Medicine's index, PubChem, FDA's own wording and the NAD+ pages of the 11 sellers on our price board, all read on October 11, 2026. It is a bounded source review, not a systematic review or individual medical advice.
Short answer
No. NAD+ is a coenzyme with no amino acids
Size
663.4 g/mol, about a fifth of sermorelin
Seller pages
11 of 11 call it a coenzyme; one headline also says peptide
Swipe the evidence table sideways to read every column.
| Record | NAD+ | Sermorelin | Semaglutide (Ozempic) |
|---|---|---|---|
| Built from | A nicotinamide unit and an adenosine unit joined through phosphate groups. No amino acids. | A chain of 29 amino acids | A peptide chain with a fatty acid side chain |
| Molecular weight | 663.4 g/mol | 3,357.9 g/mol | 4,113.58 g/mol |
| Fits FDA's description of a peptide | No | Yes | Yes |
| FDA-approved product | None listed in Drugs@FDA | Geref, since discontinued | Ozempic |
What is the difference between NAD+ and a peptide?
A peptide is made of amino acids joined by peptide bonds. The National Library of Medicine defines the class that way, and FDA's 2020 rule on biological products describes peptides and proteins alike as chains of amino acids, with the protein line drawn above 40 amino acids.
NAD+ has no amino acids to join. Its formula is C21H27N7O14P2: a nicotinamide unit and an adenosine unit, each on a ribose sugar, linked through two phosphate groups. Sermorelin, which is a peptide, is a chain of 29 amino acids and weighs about five times as much.
The two are also filed apart. The Library of Medicine's subject index places NAD under nucleotides and coenzymes and gives it no entry in the peptide branch, where sermorelin sits.
- National Library of Medicine: MeSH definition of peptides
- Federal Register: FDA's 2020 rule defining biological product, protein and peptide terms
- PubChem: NAD+ compound record, formula and molecular weight
- National Library of Medicine: MeSH definition and index entry for NAD
- National Library of Medicine: MeSH definition of sermorelin
Why is NAD+ sold as a peptide?
Mostly it is not. We read the NAD+ page of each of the 11 sellers on our price board on October 11, 2026. All 11 describe NAD+ as a coenzyme somewhere on the page.
Two pages blur it. Embody's headline promises results from "the fountain of youth peptide", and the same page later calls NAD+ "a naturally occurring coenzyme". System Labs' NAD+ page carries an FDA disclosure worded for "the peptide medications and therapies offered".
The likelier source of the mix-up is the shelf NAD+ sits on. Eight of those 11 sellers also have a sermorelin plan on our price board, and sermorelin is a peptide. Both are sold as compounded injections after an online prescription visit. Products sold side by side in the same format tend to pick up the same name. That is our reading of the pattern. None of these pages explains its wording.
Is NAD+ just vitamin B3?
No. Vitamin B3 is a raw material, and NAD+ is what the body builds from it. The National Library of Medicine describes niacin, the B3 vitamin, as required by the body for the formation of the coenzymes NAD and NADP.
NMN is another precursor and a different molecule from NAD+. The injection plans compared on this site supply NAD+ itself, and evidence for a precursor does not carry over to it.
Is NAD+ like Ozempic?
No. Ozempic's active ingredient, semaglutide, is a peptide. Its FDA label describes a GLP-1 receptor agonist with a peptide backbone and a molecular weight of 4,113.58. NAD+ weighs 663.4, contains no amino acids and is a coenzyme.
The regulatory gap is as wide as the chemical one. Ozempic is an FDA-approved product with a label. As of October 11, 2026, FDA's database of approved drugs lists no product with NAD+ as its active ingredient. Every NAD+ injection plan on this site is a compounded product, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.
Does it matter whether NAD+ is a peptide?
It matters in two places. The first is regulation. FDA sorts compounding ingredients one substance at a time. Its list of substances nominated for pharmacy compounding, updated May 14, 2026, names nicotinamide adenine dinucleotide in Category 1, substances under evaluation, next to entries such as melatonin, glutathione and coenzyme Q10. A headline about peptides joining or leaving that list tells you nothing about NAD+. Category 1 is a holding status and is not an approval.
The second is evidence. A study showing that a peptide such as sermorelin raises growth hormone says nothing about NAD+. The human NAD+ evidence is its own short list, led by a 2019 pilot in which eight men received an intravenous infusion and three received saline.
Getting the category right will not tell you whether an injection plan is worth paying for. It only stops a peptide's evidence, or a peptide's legal status, being borrowed for a molecule that is not one.
What should I ask a seller that calls NAD+ a peptide?
Ask for the product details in writing: the NAD+ concentration, the total quantity supplied for the price, the pharmacy that dispenses it and whether the product is made for sterile injection. A loose category label is not proof of a poor product, and a correct one is not proof of a good one.
FDA has reported severe reactions after injectable NAD+ made with food-grade ingredients unsuited to sterile compounding. That is a reason to ask about the ingredient grade and the dispensing pharmacy, whatever the page calls the product.
Where can I compare current NAD+ providers?
The pages below compare public product and contract information. Some are labeled partner links. Any commission we receive does not change evidence claims or table order.
Partner link; we may earn a commission. Editorial order and findings do not change.
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.
Sprout Health’s NAD+ injection referral offer excludes California.
Which sources support this answer?
Sources were checked October 11, 2026. They define the product, population and evidence limits used above; they do not determine individual suitability.
- National Library of Medicine: MeSH definition and index entry for NAD
- National Library of Medicine: MeSH definition of peptides
- Federal Register: FDA's 2020 rule defining biological product, protein and peptide terms
- PubChem: NAD+ compound record, formula and molecular weight
- PubChem: sermorelin compound record, formula and molecular weight
- National Library of Medicine: MeSH definition of sermorelin
- DailyMed: Ozempic (semaglutide) prescribing information
- FDA: Drugs@FDA database of approved drug products
- FDA: Drugs@FDA record for Geref (sermorelin acetate), listed as discontinued
- National Library of Medicine: MeSH definition of niacin (vitamin B3)
- Embody: official NAD+ injection and nasal offer
- System Labs: official NAD+ treatment page
- FDA: bulk drug substances nominated for compounding under section 503A, updated May 14, 2026
- Frontiers: human NAD+ intravenous infusion pilot
- FDA: understanding the risks of compounded drugs
- FDA: adverse event reports and ingredients used in sterile NAD+ compounding
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.